Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 8, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
Unresectable Hepatocellular Carcinoma
Interventions
DRUG

NRT6003 Injection

Selective internal radiation therapy (SIRT) with TareSphere

Trial Locations (19)

210009

Zhongda Hospital, Southeast University, Nanjing

310022

Zhejiang Cancer Hospital, Hangzhou

Unknown

Anhui Provincial Hospital, Hefei

Fujian Provincial Cancer Hospital, Fuzhou

The First Affiliated Hospital of Xiamen University, Xiamen

The First Affiliated Hospital of Jinan University, Guangzhou

Henan Cancer Hospital, Zhengzhou

Hunan Provincial People's Hospital, Changsha

The First Hospital of China Medical University, Shenyang

West China Hospital, Sichuan University, Chengdu

The Affiliated Hospital of Southwest Medical University, Luzhou

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

The First Affiliated Hospital of Wenzhou Medical University, Wenzhou

The Southwest Hospital of Army Medical University, Chongqing

Fudan University Shanghai Cancer Center, Shanghai

The First Affiliated Hospital of Naval Medical University, Shanghai

The Third Affiliated Hospital of Naval Medical University, Shanghai

Zhongshan Hospital, Fudan University, Shanghai

Tianjin Medical University Cancer Insititute & Hospital, Tianjin

All Listed Sponsors
lead

Chengdu New Radiomedicine Technology Co. LTD.

INDUSTRY

NCT06310590 - Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter